Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis
文献类型：期刊论文
| 作者 | Niu,Xia; Meng,Yanan; Cui,Jinjin; Li,Rui; Ding,Xiao; Niu,Bingyu; Chang,Ge; Xu,Ning; Li,Guiling; Wang,Yucheng |
| 刊名 | ACS NANO
 |
| 出版日期 | 2023 |
| 卷号 | 17期号:23页码:23608-23625 |
| 关键词 | liver fibrosis dihydrotanshinone I hepaticstellate cells vitamin A cyclodextrin liver microbiome STRATEGY THERAPY TARGET NANOPARTICLES PATHWAY |
| ISSN号 | 1936-086X |
| DOI | 10.1021/acsnano.3c06626 |
| 英文摘要 | Liver fibrosis is a major contributor to the morbidity and mortality associated with liver diseases, yet effective treatment options remain limited. Hepatic stellate cells (HSCs) are a promising target for hepatic fibrogenesis due to their pivotal role in disease progression. Our previous research has demonstrated the potential of Dihydrotanshinone I (DHI), a lipophilic component derived from the natural herb Salvia miltiorrhiza Bunge, in treating liver fibrosis by inhibiting the YAP/TEAD2 interaction in HSCs. However, the clinical application of DHI faces challenges due to its poor aqueous solubility and lack of specificity for HSCs. Additionally, recent studies have implicated the impact of liver microbiota, distinct from gut microbiota, on the pathogenesis of liver diseases. In this study, we have developed an HSC- and microbiome-specific delivery system for DHI by conjugating prebiotic-like cyclodextrin (CD) with vitamin A, utilizing PEG2000 as a linker (VAP2000@CD). Our results demonstrate that VAP2000@CD markedly enhances the cellular uptake in human HSC line LX-2 and enhances the deposition of DHI in the fibrotic liver in vivo. Subsequently, intervention with DHI-VAP2000@CD has shown a notable reduction in bile duct-like structure proliferation, collagen accumulation, and the expression of fibrogenesis-associated genes in rats subjected to bile duct ligation. These effects may be attributed to the regulation of the YAP/TEAD2 interaction. Importantly, the DHI-VAP2000@CD intervention has also restored microbial homeostasis in the liver, promoting the amelioration of liver inflammation. Overall, our findings indicate that DHI-VAP2000@CD represents a promising therapeutic approach for liver fibrosis by specifically targeting HSCs and restoring the liver microbial balance. |
| WOS记录号 | WOS:001124705100001 |
| 源URL | [http://ir.kib.ac.cn/handle/151853/75276]  |
| 专题 | 中国科学院昆明植物研究所 |
| 推荐引用方式 GB/T 7714 | Niu,Xia,Meng,Yanan,Cui,Jinjin,et al. Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis[J]. ACS NANO,2023,17(23):23608-23625. |
| APA | Niu,Xia.,Meng,Yanan.,Cui,Jinjin.,Li,Rui.,Ding,Xiao.,...&Wang,Lulu.(2023).Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis.ACS NANO,17(23),23608-23625. |
| MLA | Niu,Xia,et al."Hepatic Stellate Celland Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis".ACS NANO 17.23(2023):23608-23625. |
入库方式： OAI收割
来源：昆明植物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。